Investor Relations Center
Company profile
Medinice S.A. conducts research and development of innovative medical devices in cardiology. Its main projects include PacePress (a compression band used after implantation of cardiac devices), AtriClamp (a clamp for left atrial appendage closure), and CoolCryo (a cryoapplicator for cardiac surgical ablation). The Company focuses on prototype development, preclinical and clinical testing, and obtaining patents.
Stock price
Medinice S.A. shares have been listed on the Main Market of the Warsaw Stock Exchange since December 30, 2020. Previously, on September 25, 2018, the Company debuted on the NewConnect market.
Sector: medical equipment and supplies
ISIN: PLMDNCE00016
Ticker: ICE
Latest news
- 2025-09-18
Medinice signs letter of intent with U.S.-based CorNav Corporation
Medinice signed a letter of intent with US-based CorNav to collaborate on VT treatment technologies. The deal combines Medinice’s MiniMax ablation catheter with CorNav’s CardioScout navigation platform, aiming to improve safety, shorten procedures, and support Medinice’s US expansion.
- 2025-09-01
Medinice expects its latest PacePress model to be approved for the European market in 2025
Medinice expects CE-MDR approval for its latest PacePress® model in 2025. CEO Sanjeev Choudhary confirmed successful clinical results and ongoing certification work. The company is in talks with partners on commercialization in Europe, and Asia, while also exploring options for the US market.
Events and presentations
- May 30, 2025
CoolCryo video for the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2025 conference
- December 12, 2024
Summary of 2024 and Medinice's future development prospects [PL]
Previous events
Latest company reports
- The latest periodic report2025-09-12 17:57
Consolidated semi-annual report for H1-2025 PSr
- The latest current report2025-10-30 14:36 | ESPI 35/2025
Completion of patient recruitment in the clinical study of the CoolCryo medical device
- 2025-10-27 15:14ESPI | 34/2025Receiving a patent from the European Patent Office (EPO) on the invention entitled: Krioapplicator for minimally invasive cardiac ablation with a functional end
- 2025-10-09 17:13ESPI | 33/2025Announcement of the convening of an Extraordinary General Meeting of Medinice S.A. on November 6, 2025, together with draft resolutions See more reports
Additional information
General MeetingsLearn more
Corporate documentsLearn more
- Investor's calendarTimetable for the Release of Periodic Reports in 2025
- Annual report for 2024: Mar 27, 2025
- Report for Q1-2025: May 8, 2025
- Report for H1-2025: Sept 25, 2025
- Report for Q3-2025: Nov 6, 2025
Leadership TeamLearn more
- Dividend policyOn July 1, 2019, the Management Board of Medinice S.A. adopted a resolution regarding the Company’s dividend policy. In the event that the Company generates a profit eligible for distribution, the Management Board intends to annually submit a proposal to the Ordinary General Meeting for the payment of a dividend, based on the following parameters:
- Profit for distribution and total dividend payout
- 15 - 50 million PLN: at least 50% of profit to be distributed
- 50 - 100 million PLN: at least 60% of profit to be distributed
- Above 100 million PLN: at least 75% of profit to be distributed
Capital Group Structure
Investor contact
Piotr Uchman
Investor Relations Manager
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.